Compare ALEMBIC PHARMA with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs WOCKHARDT - Comparison Results

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA WOCKHARDT ALEMBIC PHARMA/
WOCKHARDT
 
P/E (TTM) x 16.0 -85.3 - View Chart
P/BV x 6.4 1.9 336.6% View Chart
Dividend Yield % 0.6 0.0 29,370.1%  

Financials

 ALEMBIC PHARMA   WOCKHARDT
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
WOCKHARDT
Mar-18
ALEMBIC PHARMA/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs6641,012 65.6%   
Low Rs412532 77.6%   
Sales per share (Unadj.) Rs208.7355.9 58.7%  
Earnings per share (Unadj.) Rs31.0-60.3 -51.4%  
Cash flow per share (Unadj.) Rs37.1-46.8 -79.4%  
Dividends per share (Unadj.) Rs5.500.01 55,000.0%  
Dividend yield (eoy) %1.00 78,867.1%  
Book value per share (Unadj.) Rs144.2257.8 55.9%  
Shares outstanding (eoy) m188.52110.63 170.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.62.2 118.9%   
Avg P/E ratio x17.4-12.8 -135.6%  
P/CF ratio (eoy) x14.5-16.5 -87.9%  
Price / Book Value ratio x3.73.0 124.7%  
Dividend payout %17.70 -106,951.6%   
Avg Mkt Cap Rs m101,46185,379 118.8%   
No. of employees `000NA6.3 0.0%   
Total wages/salary Rs m7,4679,371 79.7%   
Avg. sales/employee Rs ThNM6,295.0-  
Avg. wages/employee Rs ThNM1,498.3-  
Avg. net profit/employee Rs ThNM-1,066.3-  
INCOME DATA
Net Sales Rs m39,34739,369 99.9%  
Other income Rs m941,202 7.8%   
Total revenues Rs m39,44140,571 97.2%   
Gross profit Rs m8,73618 47,736.6%  
Depreciation Rs m1,1521,495 77.1%   
Interest Rs m1842,555 7.2%   
Profit before tax Rs m7,493-2,830 -264.8%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m1,568257 609.9%   
Profit after tax Rs m5,844-6,669 -87.6%  
Gross profit margin %22.20 47,763.5%  
Effective tax rate %20.9-9.1 -230.3%   
Net profit margin %14.9-16.9 -87.7%  
BALANCE SHEET DATA
Current assets Rs m19,57733,796 57.9%   
Current liabilities Rs m14,89626,917 55.3%   
Net working cap to sales %11.917.5 68.1%  
Current ratio x1.31.3 104.7%  
Inventory Days Days9079 113.1%  
Debtors Days Days4589 50.8%  
Net fixed assets Rs m27,09739,664 68.3%   
Share capital Rs m377553 68.1%   
"Free" reserves Rs m26,81127,968 95.9%   
Net worth Rs m27,18828,522 95.3%   
Long term debt Rs m4,99321,731 23.0%   
Total assets Rs m47,77881,620 58.5%  
Interest coverage x41.7-0.1 -38,785.6%   
Debt to equity ratio x0.20.8 24.1%  
Sales to assets ratio x0.80.5 170.7%   
Return on assets %12.6-5.0 -250.3%  
Return on equity %21.5-23.4 -91.9%  
Return on capital %23.6-7.7 -307.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,4539,807 198.4%   
Fx outflow Rs m6,0651,789 339.1%   
Net fx Rs m13,3888,019 167.0%   
CASH FLOW
From Operations Rs m8,120684 1,186.4%  
From Investments Rs m-7,5566,302 -119.9%  
From Financial Activity Rs m590-7,695 -7.7%  
Net Cashflow Rs m1,153-664 -173.7%  

Share Holding

Indian Promoters % 74.1 74.5 99.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.9 2.3 126.1%  
FIIs % 9.1 7.7 118.2%  
ADR/GDR % 0.0 0.1 -  
Free float % 13.9 15.4 90.3%  
Shareholders   49,328 67,757 72.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   SUVEN LIFE SCIENCES  SUN PHARMA  IPCA LABS  TTK HEALTHCARE  NEULAND LABS  

Compare ALEMBIC PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

A Time Correction in the Nifty(Momentum Moves)

The week belonged to the bulls after bears ended the party in February. March started with gains for the bulls but historically, March has been a bears' month.

Related Views on News

ALEMBIC PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 13.8% (Quarterly Result Update)

Jan 19, 2021 | Updated on Jan 19, 2021

For the quarter ended December 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 13.8% YoY). Sales on the other hand came in at Rs 13 bn (up 8.7% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 30.0% (Quarterly Result Update)

Oct 23, 2020 | Updated on Oct 23, 2020

For the quarter ended September 2020, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 30.0% YoY). Sales on the other hand came in at Rs 15 bn (up 17.4% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

WOCKHARDT Announces Quarterly Results (3QFY20); Net Profit Up 125.0% (Quarterly Result Update)

Jan 28, 2020 | Updated on Jan 28, 2020

For the quarter ended December 2019, WOCKHARDT has posted a net profit of Rs 192 m (up 125.0% YoY). Sales on the other hand came in at Rs 9 bn (down 16.9% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (3QFY20); Net Profit Up 33.3% (Quarterly Result Update)

Jan 23, 2020 | Updated on Jan 23, 2020

For the quarter ended December 2019, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 33.3% YoY). Sales on the other hand came in at Rs 12 bn (up 18.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 25.2% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, ALEMBIC PHARMA has posted a net profit of Rs 3 bn (up 25.2% YoY). Sales on the other hand came in at Rs 12 bn (up 10.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

More Views on News

Most Popular

It's the Beginning of a New Bull Phase in Smallcaps(Profit Hunter)

Feb 24, 2021

Last time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.

Make Rs 5,000 Per Day Trading the Market(Fast Profits Daily)

Feb 25, 2021

In this video, I'll show you how to get started on the path to daily trading profits.

The Hidden Tesla in My Great Indian Wealth Project(Profit Hunter)

Feb 23, 2021

An Indian company founded three decades ago in a garage caught my attention...

Gold 65,000 and Silver 84,000 in 2022

Feb 26, 2021

In this episode of the Investor Hour, India's #1 trader, Vijay Bhambwani, talks to us about the stock market, his new targets for gold and silver, the best long-term investment opportunity, and a lot more.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Mar 5, 2021 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS